Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Peptide therapy at Elite Plastic Surgery in Phoenix and Chandler is a medically guided, results-driven treatment offered by the Torabi brothers
Extended protocols may be appropriate for individuals with significant body composition goals, those who respond gradually to therapy, or patients seeking comprehensive metabolic optimization under close medical supervision
It is designed as a once-weekly injectable treatment for obesity, working via amylin receptors rather than the GLP-1 pathway used by most current weight loss medications
How much is 20 units of Semaglutide
BPC-157 offers theoretical mechanism without clinical validation
